Press & Publications

miReven scientists publish paper in prestigious journal Hepatology identifying new pathways that mediate resistance to sorafenib and showing that microRNA-7 can overcome therapeutic resistance in

miReven scientists show that microRNA-7 inhibits melanoma cell proliferation and metastasis and publish in Oncotarget 31 May 2016

miReven scientists have been awarded a $530,000 NHMRC Development Grant to advance miR-7 as a novel cancer therapeutic. Chief Investigators on the project Prof. Peter

MiReven scientists have published a review on Micro RNA-7 in the June 2014 edition of The International Journal of Biochemistry & Cell Biology.  The article, entitled

Perth, Western Australia (30 April, 2014)  MiReven Pty Ltd (mireven.com.au), an Australian microRNA company commercialising discoveries from the Harry Perkins Institute of Medical Research on

Perth, Western Australia, November 13, 2013 – MiReven, an Australian microRNA company commercialising discoveries from the Western Australian Institute for Medical Research (WAIMR) on the anti-cancer